CCRM Nordic engaging in ATMP-focused professional development for healthcare workers

CCRM Nordic is proud to announce its involvement in a new project aimed at developing training for healthcare professionals (HCPs) in the delivery of Advanced Therapy Medicinal Products (ATMPs). Backed by SEK 10.4 million in funding, the initiative seeks to address the growing need for specialized knowledge and skills in the rapidly advancing field of ATMPs.

The project, which was initiated in August 2024, is set to continue until August 2026. It will focus on identifying the training requirements for the existing healthcare workforce and developing the necessary measures to support the delivery of these complex treatments, including training over 500 HCPs. In addition to improving the delivery of commercially available ATMPs, the project aims to position West Sweden as an attractive location for clinical trials, boosting both local healthcare capabilities and research opportunities.

Led by Sahlgrenska Science Park, the project is a collaborative effort involving Region Västra Götaland, Sahlgrenska ATMP-centrum, Gothia Forum at Sahlgrenska University Hospital, and CCRM Nordic. The funding is provided by Environmental and Regional Development Committee of Region Västra Götaland and the European Union (through the Swedish European Social Fund Council).

For more information, please visit: https://www.sahlgrenskasciencepark.se/stories/ESF_ATMP

Contacts 

Karolina Norin (Project Manager), karolina.norin@vgregion.se 
Sara Nilsson (CCRM Nordic Representative), sara.nilsson@ccrmnordic.se 

About CCRM Nordic: 

CCRM Nordic is a leading organization dedicated to advancing research, development, and commercialization of advanced therapy medicinal products (ATMPs). With a focus on innovation and collaboration, CCRM Nordic strives to accelerate the translation of scientific discoveries into tangible therapies that address unmet medical needs. 

About CCRM: 

CCRM is a global, public-private partnership headquartered in Canada, established with seed funding provided by the Government of Canada, the Province of Ontario, and leading academic and industry partners. CCRM supports the development of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy. A network of researchers, leading companies, investors and entrepreneurs, CCRM accelerates the translation of scientific discovery into new companies and marketable products for patients, with specialized teams, dedicated funding, and unique infrastructure. In 2022, CCRM established OmniaBio Inc., a pre-clinical to commercial-stage CDMO for manufacturing gene-modified cells and viral vectors for cell and gene therapies. CCRM is hosted by the University of Toronto. Visit at ccrm.ca